5055 High efficacy of the combination of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) in HER2-positive metastatic breast cancer (MBC): updated results of an international phase II trial with a median follow-up of 39 months

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

High Efficacy ◽

Her2 Positive ◽

All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months.

10.1158/0008-5472.sabcs-6125 ◽

2009 ◽

Author(s):

N Tubiana-Mathieu ◽

P Bougnoux ◽

D Becquart ◽

A Chan ◽

F Majois ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1077 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1077-1077 ◽

Cited By ~ 4

Author(s):

L. B. Petruzelka ◽

V. Ganju ◽

D. Becquart ◽

P. F. Conte ◽

N. Tubiana-Mathieu ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Recent Analysis ◽

Her2 Positive ◽

Multicenter international phase II study of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination in HER2-positive metastatic breast cancer (MBC): updated results with a longer follow-up.

10.1158/0008-5472.sabcs-3151 ◽

2009 ◽

Author(s):

A Chan ◽

V Ganju ◽

D Becquart ◽

P Conte ◽

L Petruzelka ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Triple Combination ◽

Her2 Positive ◽

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06216-5 ◽

2021 ◽

Author(s):

Zijing Wang ◽

Jiaxuan Liu ◽

Fei Ma ◽

Jiayu Wang ◽

Yang Luo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Efficacy Study ◽

Her2 Positive ◽

Safety And Efficacy ◽

Metronomic Vinorelbine

232 Final Results of a Phase II Study of the Combination of Oral Vinorelbine (NVBo), Capecitabine (X) and Trastuzumab (H) in HER2-positive Metastatic Breast Cancer (MBC)

European Journal of Cancer ◽

10.1016/s0959-8049(12)70300-3 ◽

2012 ◽

Vol 48 ◽

pp. S110

Author(s):

L. Petruzelka ◽

V. Ganju ◽

P.F. Conte ◽

N. Tubiana-Mathieu ◽

F. Majois ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer

Cancer Investigation ◽

10.3109/07357901003631031 ◽

2010 ◽

Vol 28 (8) ◽

pp. 865-871 ◽

Cited By ~ 5

Author(s):

Denise A. Yardley ◽

Davey Daniel ◽

Michael Stipanov ◽

D. Randolph Drosick ◽

Mark Mainwaring ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Her2 Positive

Three-Year Follow-Up of Survival and Progression in a Phase II Trial of Gemcitabine Plus Carboplatin (Plus Trastuzumab in HER2+ Patients) in Metastatic Breast Cancer Patients.

10.1158/0008-5472.sabcs-09-2105 ◽

2009 ◽

Author(s):

D. Loesch ◽

L. Asmar ◽

K. McIntyre ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Breast Cancer Patients

Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab

10.1158/1538-7445.sabcs17-pd3-08 ◽

2018 ◽

Cited By ~ 4

Author(s):

B Xu ◽

F Ma ◽

Q Ouyang ◽

W Li ◽

Z Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Her2 Positive ◽

Randomized Phase Ii ◽

Previously Treated

Abstract PD3-03: SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer

10.1158/1538-7445.sabcs18-pd3-03 ◽

2019 ◽

Cited By ~ 5

Author(s):

E Ciruelos ◽

P Villagrasa ◽

L Paré ◽

M Oliveira ◽

S Pernas ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Her2 Positive ◽

Stage 1

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)

Annals of Oncology ◽

10.1093/annonc/mdy272.280 ◽

2018 ◽

Vol 29 ◽

pp. viii93 ◽

Cited By ~ 4

Author(s):

J. Huober ◽

P. Weder ◽

C. Veyret ◽

B. Thürlimann ◽

A. Xyrafas ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Open Label Phase